ISCOM technology in vaccine development
Vaccine development
Isconova meet the need of effective adjuvants with an industrially proven high performance novel adjuvant, for the development of successful and innovative vaccines.
Isconova has greatly improved the ISCOM technology and new patents forms the third generation ISCOM technology with superior safety performance. Isconova’s adjuvants are safe, efficient and most important of all: proven.
Vaccine developers stress the importance of efficient, safe and innovative vaccines. Today Freund’s adjuvant is commonly used in research phase. However, the unapproved Freund’s adjuvant must be changed to the proven but less efficient Alum adjuvant when initiating clinical studies. Consequently, the adjuvant switch increases both vaccine development time and development costs.
As a solution, Isconova can provide you with an adjuvant technology platform that ensures an efficient research phase and a proven adjuvant that allows you to initiate clinical trials. The use of Isconova’s adjuvant will save your development time, cut development costs and drive your new vaccine faster to market.
Antigen saving technology
Isconova’s adjuvant technology is antigen sparing. The adjuvant makes it possible to use lower doses of antigen, which would allow for cheaper vaccines. In addition, the antigen saving properties make it easy to produce more vaccine even if the antigen is difficult or expensive to produce.
Combination of live and killed vaccine components
Isconova’s Matrix can be combined with live attenuated vaccine antigens without impeding the proliferation of the live vaccine antigens. This creates an opportunity to use the adjuvant system in a mixture of live and killed vaccine antigens.
Vaccines for difficult infections and for immunocompromised groups.
Isconova’s adjuvant is efficacious and safe even for immunocompromised groups such as juveniles and elderly (See RSV vaccine candidate). The adjuvant technology generates a broad, strong and long protection, an advantage particular in induviduals with weak immune systems. When conventional vaccines have failed, recent experimental ISCOM vaccine formulations have been shown to overcome two key obstacles for successful immunization of infants. e.g. the maturity of the immune system and the interfering passively derived maternal antibodies.